Pediatric primitive neuroectodermal tumors of the central nervous system differentially express granzyme inhibitors

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Vermeulen, Jeroen F ^a   Hecke, Wim Van ^a   Spliet, Wim G M ^a   Hidalgo, José Villacorta ^b   Fisch, Paul ^b   Broekhuizen, Roel ^a   Bovenschen, Niels ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; GRANZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR B1; SERINE PROTEINASE INHIBITOR B4; SERINE PROTEINASE INHIBITOR B9; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL SURFACE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; NEUROECTODERM TUMOR; PRESCHOOL CHILD; PRIMITIVE NEUROECTODERMAL TUMOR; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; GENE EXPRESSION REGULATION; IMMUNOLOGY; NEUROECTODERMAL TUMORS, PRIMITIVE; PATHOLOGY; TUMOR ESCAPE;

ADOLESCENT; ANTIGENS, CD1D; BRAIN NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; NEOPLASM PROTEINS; NEUROECTODERMAL TUMORS, PRIMITIVE; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SERINE PROTEINASE INHIBITORS; SERPINS; TUMOR ESCAPE;

EID: 84962529567     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151465     Document Type: Article

References (31)

1. De Braganca KC, Packer RJ. Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET). Curr Treat Options Neurol. 2013;15(5):593-606. doi: 10.1007/s11940-013-0255-4 PMID: 23979905.
2. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465-72. doi: 10.1007/s00401-011-0922-z PMID: 22134537.
3. Picard D, Miller S, Hawkins CE, Bouffet E, Rogers HA, Chan TS, et al. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol. 2012;13(8):838-48. doi: 10.1016/S1470-2045 (12) 70257-7 PMID: 22691720.
4. Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci. 2012;19(11):1541-4. doi: 10.1016/j.jocn. 2012.04.009 PMID: 22981874.
5. Johnston DL, Keene DL, Lafay-Cousin L, Steinbok P, Sung L, Carret AS, et al. Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report. J Neurooncol. 2008;86(1):101-8. doi: 10.1007/s11060-007-9440-1 PMID: 17619825.
6. Timmermann B, Kortmann RD, Kuhl J, Rutkowski S, Meisner C, Pietsch T, et al. Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT-SKK87 and HIT-SKK92 trials. J Clin Oncol. 2006;24(10):1554-60. doi: 10.1200/JCO.2005.04.8074 PMID: 16575007.
7. Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. Neuro Oncol. 2013;15(1):97-103. doi: 10.1093/neuonc/nos267 PMID: 23099653.
8. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002;71(6):907-20. PMID: 12050175.
9. Raffaghello L, Nozza P, Morandi F, Camoriano M, Wang X, Garre ML, et al. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Res. 2007;67(11):5471-8. doi: 10.1158/0008-5472. CAN-06-4735 PMID: 17545629.
10. Gerosa MA, Amadori G, Semenzato P, Gasparotto G, Carteri A. Immunobiology of primary CNS tumors in infancy and childhood. B- and T-cell dependent immunity and cytotoxicity and cell kinetic evaluation. Childs Brain. 1980;6(2):92-102. PMID: 6965475.
11. Liu D, Song L, Brawley VS, Robison N, Wei J, Gao X, et al. Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. Clin Immunol. 2013;149(1):55-64. doi: 10.1016/j.clim. 2013.06.005 PMID: 23891738.
12. Sapoznik S, Hammer O, Ortenberg R, Besser MJ, Ben-Moshe T, Schachter J, et al. Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol. 2012;2012:818214. doi: 10.1155/2012/818214 PMID: 22778766.
13. Van Houdt IS, Oudejans JJ, Van Den Eertwegh AJ, Baars A, Vos W, Bladergroen BA, et al. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res. 2005;11(17):6400-7. doi: 10.1158/1078-0432. CCR-05-0306 PMID: 16144945.
14. CCMO website:. Central Committee on Research involving Human Subjects (Centrale Commissie Mensgebonden Onderzoek) (text in Dutch): http://www.ccmo.nl/nl/uw-onderzoek-wmo-plichtig-of-niet [2015 September 2].
15. Van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. For. BMJ. 2002;325(7365):648-51.
16. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science. 2005;309(5732):264-8. doi: 10.1126/science.1110267 PMID: 15933162.
17. Chien YH, Meyer C, Bonneville M. gammadelta T cells: first line of defense and beyond. Annu Rev Immunol. 2014;32:121-55. doi: 10.1146/annurev-immunol-032713-120216 PMID: 24387714.
18. Vaquero J, Coca S, Oya S, Martinez R, Ramiro J, Salazar FG. Presence and significance of NK cells in glioblastomas. J Neurosurg. 1989;70(5):728-31. doi: 10.3171/jns.1989.70.5.0728 PMID: 2540292.
19. Poli A, Kmiecik J, Domingues O, Hentges F, Blery M, Chekenya M, et al. NK cells in central nervous system disorders. J Immunol. 2013;190(11):5355-62. doi: 10.4049/jimmunol.1203401 PMID: 23687193.
20. Uldrich AP, Le Nours J, Pellicci DG, Gherardin NA, McPherson KG, Lim RT, et al. CD1d-lipid antigen recognition by the gammadelta TCR. Nat Immunol. 2013;14(11):1137-45. doi: 10.1038/ni.2713 PMID: 24076636.
21. Bovenschen N, Kummer JA. Orphan granzymes find a home. Immunol Rev. 2010;235(1):117-27. doi: 10.1111/j.0105-2896.2010.00889.x PMID: 20536559.
22. Wang L, Li Q, Wu L, Liu S, Zhang Y, Yang X, et al. Identification of SERPINB1 as a physiological inhibitor of human granzyme H. J Immunol. 2013;190(3):1319-30. doi: 10.4049/jimmunol.1202542 PMID: 23269243.
23. De Koning PJ, Kummer JA, De Poot SA, Quadir R, Broekhuizen R, McGettrick AF, et al. Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death. PLoS One. 2011;6(8):e22645. doi: 10.1371/journal.pone.0022645 PMID: 21857942.
24. Medema JP, De Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(20):11515-20. doi: 10.1073/pnas.201398198 PMID: 11562487.
25. Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014;156(5):1002-16. doi: 10.1016/j.cell.2014.01. 040 PMID: 24581498.
26. Huasong G, Zongmei D, Jianfeng H, Xiaojun Q, Jun. G, Sun G, et al. Serine protease inhibitor (SERPIN) B1 suppresses cell migration and invasion in glioma cells. Brain research. 2015;1600:59-69. doi: 10. 1016/j.brainres.2014.06.017 PMID: 24968089.
27. McGettrick AF, Barnes RC, Worrall DM. SCCA2 inhibits TNF-mediated apoptosis in transfected HeLa cells. The reactive centre loop sequence is essential for this function and TNF-induced cathepsin G is a candidate target. European journal of biochemistry/FEBS. 2001;268(22):5868-75. PMID: 11722574.
28. Murakami A, Suminami Y, Hirakawa H, Nawata S, Numa F, Kato H. Squamous cell carcinoma antigen suppresses radiation-induced cell death. British journal of cancer. 2001;84(6):851-8. doi: 10.1054/bjoc.2000.1683 PMID: 11259103.
29. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol. 1990;2(2):113-25. PMID: 2088481.
30. Bladergroen BA, Strik MC, Bovenschen N, Van Berkum O, Scheffer GL, Meijer CJ, et al. The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J Immunol. 2001;166(5):3218-25. PMID: 11207275.
31. Kummer JA, Kamp AM, Tadema TM, Vos W, Meijer CJ, Hack CE. Localization and identification of granzymes A and B-expressing cells in normal human lymphoid tissue and peripheral blood. Clin Exp Immunol. 1995;100(1):164-72. PMID: 7697916.